The $800 Million Pill: The Truth Behind the Cost of New Drugs
Why do life-saving prescription drugs cost so much? Drug companies insist that prices reflect the millions they invest in research and development. In this gripping exposť, Merrill Goozner contends that American taxpayers are in fact footing the bill twice: once by supporting government-funded research and again by paying astronomically high prices for prescription drugs. Goozner demonstrates that almost all the important new drugs of the past quarter-century actually originated from research at taxpayer-funded universities and at the National Institutes of Health. He reports that once the innovative work is over, the pharmaceutical industry often steps in to reap the profit.
Goozner shows how drug innovation is driven by dedicated scientists intent on finding cures for diseases, not by pharmaceutical firms whose bottom line often takes precedence over the advance of medicine. A university biochemist who spent twenty years searching for a single blood protein that later became the best-selling biotech drug in the world, a government employee who discovered the causes for dozens of crippling genetic disorders, and the Department of Energy-funded research that made the Human Genome Project possible--these engrossing accounts illustrate how medical breakthroughs actually take place.
The $800 Million Pill suggests ways that the government's role in testing new medicines could be expanded to eliminate the private sector waste driving up the cost of existing drugs. Pharmaceutical firms should be compelled to refocus their human and financial resources on true medical innovation, Goozner insists. This book is essential reading for everyone concerned about the politically charged topics of drug pricing, Medicare coverage, national health care, and the role of pharmaceutical companies in developing countries.
What people are saying - Write a review
The $800 million pill: the truth behind the cost of new drugsUser Review - Not Available - Book Verdict
American expenditures on prescription drugs doubled between 1990 and 2000 and currently account for close to ten percent of total healthcare costs. Concerns about availability to seniors and the ... Read full review
Other editions - View all
Abbott academic ACTG agency AIDS activists AIDS patients AIDS research American Amgen basic began biotech biotechnology blood cell Brady Center chemical chemists chemotherapy clinical trials company’s cost cure decade Desnick discovery doctors dollars dose drug companies drug development drug industry drug’s early enzyme Epogen Erickson erythropoietin eventually Fabry disease FDA approval federal firms funded Gaucher Gaucher disease gene patents Genentech genetic Goldwasser government’s Hoffmann–La Roche Human Genome hundred indinavir industry’s innovation Institute Interview Kempf later licensed machines major manufacturing me-too drugs medicine ment Merck million molecule National NCI’s NSAIDs Office orphan drugs percent physicians potential protease inhibitor protein research and development ritonavir Roche Roche’s saquinavir scientific scientists Scolnick sequencing Slamon start-up targets Taxol therapy thousand treatment tumors University viral virus Wall Street Journal wanted